CKD Bio Corp
063160
Company Profile
Business description
CKD Bio Corp is engaged in producing high-quality raw pharmaceutical ingredients, such as antibiotics and immunosuppressants, and supply them to domestic and international pharmaceutical companies. The company also purchases finished pharmaceutical products from domestic and international markets for export and domestic supply.
Contact
8 Chungjeong-ro, 3-ga Chungjeong-ro
Seodaemun-gu
Seoul
KORT: +82 221940555
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
530
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,856.30 | 6.00 | 0.07% |
| CAC 40 | 8,117.42 | 135.66 | 1.70% |
| DAX 40 | 24,737.24 | 336.59 | 1.38% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,432.34 | 101.79 | 0.99% |
| HKSE | 25,620.58 | 30.54 | -0.12% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,945.34 | 2,140.93 | 3.58% |
| NZX 50 Index | 12,803.41 | 42.38 | 0.33% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,635.50 | 7.50 | 0.09% |
| SSE Composite Index | 4,174.79 | 12.61 | 0.30% |